secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001104659-24-084206
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entero Therapeutics provides latiglutenase Phase 3 plan, FDA meetings, $1.9M raise
--------------------------------------------------------------------------------

- Submits Type D requests to FDA to streamline Phase 3 trial cohorts from three to two (1200 mg and placebo).
- Second Type D request seeks FDA agreement on histology secondary endpoints based on Phase 2 results.
- Raised $1.9 million in gross proceeds from a small financing to support Phase 3 trial initiation.
- Consolidated bi-coastal operations into Boca Raton HQ to reduce overhead costs.
- CEO James Sapirstein reaffirms goal to start pivotal Phase 3 trial for latiglutenase in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924084206/0001104659-24-084206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924084206/tm2420546d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-084206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer